Pharmacogenetics of beta-blockers.

Article Details

Citation

Copy to clipboard

Shin J, Johnson JA

Pharmacogenetics of beta-blockers.

Pharmacotherapy. 2007 Jun;27(6):874-87. doi: 10.1592/phco.27.6.874.

PubMed ID

17542770 [ View in PubMed

]

Abstract

Beta-blockers are an important cardiovascular drug class, recommended as first-line treatment of numerous diseases such as heart failure, hypertension, and angina, as well as treatment after myocardial infarction. However, responses to a beta-blocker are variable among patients. Results of numerous studies now suggest that genetic polymorphisms may contribute to variability in responses to beta-blockers. This review summarizes the pharmacogenetic data for beta-blockers in patients with various diseases and discusses the potential implications of beta-blocker pharmacogenetics in clinical practice.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Labetalol	Cytochrome P450 2D6	Protein	Humans	Unknown	Substrate Inhibitor	Details

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Acebutolol Rifampicin	The metabolism of Acebutolol can be increased when combined with Rifampicin.
Acebutolol Rifapentine	The metabolism of Acebutolol can be increased when combined with Rifapentine.
Acebutolol Rifaximin	The metabolism of Acebutolol can be increased when combined with Rifaximin.
Acebutolol Rifamycin	The metabolism of Acebutolol can be increased when combined with Rifamycin.
Acebutolol 25-desacetylrifapentine	The metabolism of Acebutolol can be increased when combined with 25-desacetylrifapentine.